2014 Annual Meeting: Panelists and Speakers

Amy P. Abernethy, MD PhD
Director, Duke Center for Learning Health Care

Margaret Anderson
Executive Director, FasterCures

Robert D. Atkinson, PhD
President, ITIF

Christopher P. Austin, M.D.
Director, National Center for Advancing Translational Sciences

Joel W. Beetsch, PhD
Vice President, Patient Advocacy, Corporate Affairs, Celgene Corporation

Jonathan Blum
Centers for Medicare & Medicaid Services, Principal Deputy Administrator

Marc M. Boutin, JD
Executive Vice President and Chief Operating Officer , National Health Council

Samantha Budd, PhD
Vice President , Translational Sciences Neuroscience iMed

Chet Burrell
President and Chief Executive Officer , CareFirst BlueCross BlueShield

John Castellani
President & CEO, PhRMA

Michael Chui
Partner, McKinsey Global Institute

Deirdre Connelly
President, North American Pharmaceuticals , GlaxoSmithKline

Glen De Vries
President, Medidata Solutions

Joaquin Duato
Worldwide Chairman, Pharmaceuticals Group , Johnson & Johnson

Jennifer Finnegan McCafferty, Ph.D.
VP, Consumer Health Supply Chain, GlaxoSmithKline

Margaret Hamburg
Commissioner, FDA

Colin Hill
CEO & President, GNS Healthcare

Mitch Horowitz
Vice President & Managing Director, Battelle Technology Partnership Practice

Robert J. Hugin
Chairman and CEO, Celgene Corporation

Suleika Jaouad
Author, "Life, Interrupted"

Richard Kingham
Partner, Covington & Burlington LLP

John C. Lechleiter, Ph.D.
Chairman, President, & CEO, Eli Lilly & Company

Jonathan S. Leff
Partner, Deerfield Management

J. Leonard Lichtenfeld
MACP Deputy Chief Medical Officer , American Cancer Society, Inc.

Terry McAuliffe
Governor, Virginia

Craig C. Mello, Ph.D.
Investigator, Howard Hughes Medical Institute

Jessica Melore
Motivational Speaker, Heart Attack Survivor

Ambassador Hugo Paemen
Consultant, Brussels,

Eric Perakslis, PhD
Executive Director, Center for Biomedical Informatics & Countway Library of Medicine, Harvard Medical School

Tomas J. Philipson
Daniel Levin Professor of Public Policy Studies , Irving B. Harris Graduate School of Public Policy Studies University of Chicago

Richard F. Pops
CEO and Director, Alkermes, Inc.

Daniel M. Price
Managing Director , Rock Creek Global Advisors LLC

Ian Read
CEO, Pfizer

Geralyn S. Ritter
Senior Vice President, Global Public Policy & Corporate Responsibility, Secretary and Assistant General Counsel , Merck & Co., Inc.

Carl Schmid
Deputy Executive Director, The AIDS Institute

Wendy K.D. Selig
President and CEO, Melanoma Research Alliance

Daniel Tassé
Chairman and CEO, Ikaria

Sharon F. Terry
President and CEO , Genetic Alliance

Kenneth Thorpe, PhD
Robert W. Woodruff Professor and Chair, Rollins School of Public Health

Fred Upton
Chairman , House Energy and Commerce Committee

Mark Velleca, M.D., Ph.D.
Executive Vice President, Chief Policy & Advocacy Officer , The Leukemia & Lymphoma Society (LLS)

Amy P. Abernethy, MD PhD
Director, Duke Center for Learning Health Care

Amy P. Abernethy, MD PhD, a hematologist/oncologist and palliative care physician, is Director of the Duke Center for Learning Health Care (CLHC) in the Duke Clinical Research Institute, and Director of the Duke Cancer Care Research Program (DCCRP) in the Duke Cancer Institute. With over 350 publications, she is an internationally recognized expert in health services research, comparative effectiveness research, clinical informatics and patient-centered care. 

Dr. Abernethy is an appointee to the Institute of Medicine’s National Cancer Policy Forum, President of the American Academy of Hospice & Palliative Medicine (AAHPM), Secretary of the Board of Directors for the Personalized Medicine Coalition, Chair of the Advisory Board for the Rapid Learning System for Cancer of the American Society of Clinical Oncology (ASCO’s CancerLinQ), Co-Chair of the National Institutes of Health (NIH)-funded Palliative Care Research Cooperative Group, Co-Chair of the Patient

Reported Outcomes (PRO) Core for the NIH Collaboratory Program, Chair of the PRO Task Force for the Patient Centered Outcomes Research Institute National Clinical Research Network, and Principal Investigator of ASCO/AAHPM Virtual Learning Collaborative for Palliative Care.   Dr. Abernethy participates integrally in current high-level national and international discussions about reforming the evidence development system, presenting a model for a rapid learning cancer care that coordinates clinical and research functions to better serve patients’ needs in an evidence-driven, cost-effective, and patient-centered manner. 

×

Margaret Anderson
Executive Director, FasterCures

Margaret Anderson is the executive director of FasterCures, a Milken Institute center that works to speed up the timeline for new medicines to go from discovery to patients. She is a founding board member and past‐president of the Alliance for a Stronger FDA, is a member of the NIH National Center for Advancing Translational Sciences (NCATS) Advisory Council and Cures Acceleration Network Review Board, the National Health Council Board of Directors, United for Medical Research Steering Committee, and the Institute of Medicine's Forum on Drug Discovery, Development and Translation. Previously, Anderson was the deputy director and a team leader in the Center on AIDS & Community Health at the Academy for Educational Development, where she led public health projects; program director at the Society for Women’s Health Research; health science analyst at the American Public Health Association, where she managed a programmatic portfolio on HIV/AIDS and other sexually transmitted diseases, infectious diseases, women’s health, and public health infrastructure issues; and analyst and project director at the Congressional Office of Technology Assessment in the Biological Applications Program, where she studied societal and business implications of genetic testing. Anderson holds a bachelor's degree from the University of Maryland and a master's degree in science, technology, and public policy from George Washington University.

×

Robert D. Atkinson, PhD
President, ITIF

Dr. Robert D. Atkinson is one of the country’s foremost thinkers on innovation economics. With an extensive background in technology policy, he has conducted ground‐breaking research projects on technology and innovation, is a valued adviser to state and national policy makers, and a popular speaker on innovation policy nationally and internationally. He is the author of Innovation Economics: The Race for Global Advantage (Yale, 2012) and The Past and Future of America’s Economy: Long Waves of Innovation That Power Cycles of Growth (Edward Elgar, 2005). Before coming to ITIF, Atkinson was Vice President of the Progressive Policy Institute and Director of PPI’s Technology & New Economy Project. Ars Technica listed Atkinson as one of 2009’s Tech Policy People to Watch. He has testified before a number of committees in Congress and has appeared in various media outlets including CNN, Fox News, MSNBC, NPR, and NBC Nightly News.

×

Christopher P. Austin, M.D.
Director, National Center for Advancing Translational Sciences

In September 2012, NIH Director Francis S. Collins announced the appointment of Christopher P. Austin, M.D., as director of the National Center for Advancing Translational Sciences (NCATS). Austin succeeded former acting director of NCATS and current director of the National Institute of Mental Health Thomas R. Insel, M.D.

Austin, who served as director of the NCATS Division of Pre‐Clinical Innovation since the creation of the Center in December 2011, is leading NCATS in its mission to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Currently, many costly, time‐consuming bottlenecks exist in the translational pipeline. Austin is applying his experiences in nearly every stage of the research pipeline to build on the Center’s momentum in finding innovative ways to reduce, remove or bypass these bottlenecks and speed the delivery of new drugs, diagnostics and medical devices to patients.

After working at Merck on genome‐based discovery of novel targets and drugs, Austin began his NIH career in 2002 as the senior advisor to the director for translational research at the National Human Genome Research Institute, where he initiated the Knockout Mouse Project and the Molecular Libraries Roadmap Initiative. Other NIH roles have included serving as director of the Therapeutics for Rare and Neglected Diseases program as well as the NIH Chemical Genomics Center and as scientific director of the NIH Center for Translational Therapeutics.

Austin earned a medical degree from Harvard Medical School and an undergraduate degree in biology from Princeton University. He completed clinical training in internal medicine and neurology at Massachusetts General Hospital as well as a fellowship in genetics at Harvard. 

×

Joel W. Beetsch, PhD
Vice President, Patient Advocacy, Corporate Affairs, Celgene Corporation

Joel Beetsch currently holds the position of Vice President of Patient Advocacy within the Celgene Corporate Affairs Department.  In this position, Dr. Beetsch leads the global development and execution of a coordinated patient-focused Advocacy strategy working with multiple patient, provider, payer, and policy organizations to foster safe and effective solutions to healthcare challenges.   These efforts drive the assurance that patient access to healthcare solutions and medical innovation and are valued and advanced.

During his 15 year tenure in the biopharmaceutical industry, Dr. Beetsch has held several Medical and Corporate Affairs positions.  Joel has professional interests in patient-focused care coordination, health policy, and the use of health information technology.

Joel earned his Doctorate in Neurobiology/Biochemistry from the Boonshoft School of Medicine at Wright State University.  Following his doctoral work, Dr. Beetsch was further trained in cellular physiology at the Washington University School of Medicine in St. Louis.

×

Jonathan Blum
Centers for Medicare & Medicaid Services, Principal Deputy Administrator

Jonathan (Jon) Blum currently serves as the Principal Deputy Administrator at the Centers for Medicare & Medicaid Services (CMS). Jon is responsible for coordinating CMS’s policy centers and offices to develop and execute strategies to improve payment and the delivery of care across the agency, impacting national Medicare, Medicaid, and health insurance marketplace policy. 

From 2009‐2013, Jon served as the Director of the Center for Medicare at CMS, overseeing the regulation and payment of Medicare fee‐for service providers, privately‐administered Medicare health plans, and the Medicare prescription drug program. He led the implementation of many significant Medicare reforms, including the Medicare Shared Savings Program (ACOs), the Medicare Advantage Quality Bonus Program, competitive bidding for durable medical supplies, new bundled payment initiatives, and the Medicare prescription drug discount program. 

Prior to arriving at CMS, Jon worked as a program analyst at the Office of Management and Budget, focusing on the Medicare program. He served on the professional staff of the Senate Finance Committee, advising its current chairman, Senator Max Baucus on prescription drug and Medicare Advantage policies during the development of the Medicare Modernization Act. He was also a Vice President at Avalere Health, overseeing its Medicaid and Long‐Term Care Practice. 

Jon holds a Master's degree from Harvard’s Kennedy School of Government and a BA from the University of Pennsylvania. 

×

Marc M. Boutin, JD
Executive Vice President and Chief Operating Officer , National Health Council

Marc Boutin is the executive vice president and chief operating officer of the National Health Council, an organization that brings together all segments of the health care community to provide a united voice for the more than 133 million people with chronic diseases and disabilities and their family caregivers. 

In addition to overseeing financial management and operations at the National Health Council (NHC), Boutin builds consensus among member patient advocacy organizations enabling them to speak with one voice on systemic health research and health care policy initiatives. This united effort results in legislation and regulations that address the collective needs of patients and their family caregivers. In addition, he provides guidance to patient organizations on various association issues, including corporate structure, government relations, fundraising, and outreach. Boutin is a regular spokesperson before the media, Congress, and policy makers on major issues of interest to the patient community.

Boutin has been actively involved in health advocacy, policy, and both federal and state legislation throughout his career. He is a member the International Alliance of Patients’ Organizations Governing Board, Community Health Charities Board of Directors, PCORI Advisory Panel on Patient Engagement and the North America Advisory Board to the Drug Information Association. He has also served on Institute of Medicine committees, National Institute of Health panels, and the Agency for Healthcare Research and Quality’s stakeholder group.

×

Samantha Budd, PhD
Vice President , Translational Sciences Neuroscience iMed

An industry leading expert in neurodegeneration, Samantha joined AstraZeneca as a Research Scientist in 2000 and has since then worked in several senior scientific, project and leadership roles. Her current role is Vice President Translational Sciences in the Neuroscience iMed, and global project lead for the Beta secretase program currently completing Ph1 for Alzheimer’s disease.  

Prior to the move to Boston and the Neuroscience iMed, Samantha was VP Translational Science in the CNS&Pain iMed in Sodertalje where she established the Translational Science function and contributed significantly to the development of Translational Science expertise and capabilities in AstraZeneca. Samantha has also been a main architect of several key innovative partnerships in the Neuroscience therapeutic area.   As Disease Area Leader and member of the Alzheimer’s & Cognition Early Portfolio Team (2006‐2010), Samantha has seen more than 20 Candidate Drugs through preclinical testing, and many of these into clinical testing. During this time Samantha led the Amyloid PET Ligand Development taking this biomarker & diagnostic program into Ph2.  

Samantha has a BSc and PhD in Biochemistry from the University of Dundee in Scotland, and conducted research at the Neurosurgery Department, Brigham & Women’s Hospital, Harvard Medical School in Boston, and The Center for Neuroscience Research at The Burnham Institute in San Diego.

×

Chet Burrell
President and Chief Executive Officer , CareFirst BlueCross BlueShield

Chet Burrell, joined CareFirst BlueCross BlueShield in December 2007. He is a seasoned professional with more than 40 years in the health care industry.  His experience includes serving as President and Chief Executive Officer of RealMed Corporation, a provider of online claims processing services and founder; and Chairman and CEO for Novalis Corporation, a managed care technology and consulting company.  He has also served in senior‐level positions for Anthem and Empire Blue Cross Blue Shield plans and Blue Cross of Northeastern New York.  In addition to his private sector health care experience, Burrell has also served in the New York State government in a variety of capacities, including the Offices of Mental Health and Health Systems Management and as a member of the New York Governor’s Staff.

Burrell earned his Bachelor’s degree in Sociology and Political Science from Allegheny College and a Master’s   degree in Public Administration from the University of Albany.  Burrell serves on the Boards of the DC Chamber of Commerce, the Greater Baltimore Committee’s Executive and Health Care Committees, the Greater Washington Board of Trade and the Council for Affordable Quality Healthcare (CAQH).  

×

John Castellani
President & CEO, PhRMA

John J. Castellani is President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), an organization that represents America’s leading biopharmaceutical research companies.  The biopharmaceutical sector directly employs over 650,000 Americans working to develop new medicines that help patients fight disease and live, longer healthier lives.

Working at the intersection of public policy, health and business, Mr. Castellani leads PhRMA’s efforts to preserve and strengthen a healthcare and economic environment that fosters medical innovation, new drug discovery and access to life-saving medicines. He is a passionate advocate for a strong, innovative and growing American biopharmaceutical research industry that plays a critical role in helping to improve the health of every American and patients the world-over.

In 2011, Mr. Castellani was recognized by The Hill newspaper as one of America’s top health care lobbyists. He also was honored with the Bryce Harlow Foundation’s prestigious 2011 Business-Government Relations Award, recognizing his leadership and exemplary life-long contribution to the public affairs and advocacy profession.

Mr. Castellani is a former President and CEO of Business Roundtable, an association of chief executive officers of leading U.S. corporations with a combined workforce of nearly 12 million employees and $6 trillion in annual revenues. 

Prior to Business Roundtable, Mr. Castellani was Executive Vice President of Tenneco, Inc.

Mr. Castellani, who began his career as an environmental scientist at General Electric, earned his bachelor’s degree at Union College in Schenectady, New York.

×

Michael Chui
Partner, McKinsey Global Institute

Michael Chui is a Partner at the McKinsey Global Institute. He is based in San Francisco, CA, where he directs research on the impact of long‐term disruptive technology trends, such as Big Data and Open Data, social media, and the Internet of Things, on business, the economy and society. He has served clients in the High Tech, Media and Telecom industries on strategy, innovation and product development, IT, sales & marketing, M&A and organization. Michael is a frequent speaker at major global conferences and his research has been cited in publications such as the Wall Street Journal, New York Times, Financial Times, Fast Company, Forbes, The Economist, The Times of London, WIRED, and Les Échos.

Michael holds a B.S. in Symbolic Systems from Stanford University and earned a Ph.D. in Computer Science and Cognitive Science, and a M.S. in Computer Science, from Indiana University. His Ph.D. dissertation, entitled “I Still Haven’t Found What I’m Looking For: Web Searching as Query Refinement,” examined Web user search behaviors and the usability of Web search engines.

Prior to joining McKinsey, Michael served as the first Chief Information Officer of the City of Bloomington, Indiana, where he re‐architected the enterprise architecture using Open Source technologies and led a project that resulted in Bloomington becoming the first community in the world to offer both live and archived video streaming of public meetings on the Web.

Before that, Michael was founder and executive director of HoosierNet, Inc, a nonprofit cooperative Internet service provider that provided dial‐up and broadband access to the Internet to consumers, nonprofits, governments and businesses.

×

Deirdre Connelly
President, North American Pharmaceuticals , GlaxoSmithKline

Deirdre Connelly joined GSK as President, North American Pharmaceuticals, on 9

February 2009.  She reports to Andrew Witty, Chief Executive Officer and is a member of GSK’s Corporate Executive Team.

Prior to this, Deirdre was appointed President of US operations at Eli Lilly and Company in 2005.  Previously she was senior vice president for Human Resources for Lilly.  She had joined Lilly in 1983 as a sales representative and moved to San Juan as a marketing associate a year later.  After progressing through sales and marketing roles of increasing responsibility, including Lilly’s international management development program, she was promoted to General Manager for Eli Lilly Puerto Rico, SA, in 1995.

From 1997 to 2001, she held positions of regional sales director, executive director of global marketing for Evista, (an osteoporosis treatment for post‐menopausal women) and was promoted to leader of the woman’s health business unit in the US affiliate. In 2003, she became executive director of human resources for the US affiliate, joining the company’s policy committee in 2004.

A native of San Juan, Deirdre received a bachelor's degree in economics and marketing from Lycoming College in Pennsylvania in 1983. She graduated from the Harvard University's Advanced Management Program in 2000.  Deirdre is a member of the Board of Directors of Macy’s Inc., the US department store chain. 

×

Glen De Vries
President, Medidata Solutions

Glen is one of the founders of Medidata Solutions and the original architect of the Medidata Rave® system. Since the company's inception, Glen has been responsible for driving Medidata's technology vision and the delivery of a growing platform of cloud‐based clinical solutions, inspiring the growth of the organization’s world‐class development team and building the company's critical sponsor and partner relationships. Under his leadership, Medidata is leading the transformation of the industry’s approach to clinical development and helping to define the future state of life sciences.

Prior to his work with Medidata Solutions, Glen’s pioneering efforts in online physician/patient relationships included over 10 years of experience in medical software development, including electronic health records and consumer‐targeted products. As a research assistant at Columbia University, he focused on both research science and medical informatics, working on a blood assay for the detection of micro‐metastases in prostate cancer patients and creating a  paperless CDM system. His peer‐reviewed papers have been published in Applied Clinical Trials, Cancer, The Journal of Urology, Molecular Diagnostics, Urology and Urologic Clinics of North America.

Glen received his BS in molecular biology and genetics from Carnegie Mellon University and   also studied probabilistic algorithms at the Courant Institute of Mathematics (New York University). In addition to authoring issued patents for clinical trial innovations, he has received many accolades for his industry commitment, including FierceBiotech’s Top Ten Biotech Techies in 2012, the PharmaVOICE 100 Most Inspiring People in 2006, Crain’s New York Business 40 Under 40 of 2010, and the Ernst & Young Entrepreneur Of The Year award for the metro New York area in both 2006 and 2010. He is chairman of the board for Dancing Classrooms, a not‐ for‐profit organization that seeks to cultivate essential life skills in children through the practice of social dance.

×

Joaquin Duato
Worldwide Chairman, Pharmaceuticals Group , Johnson & Johnson

Joaquin Duato is Worldwide Chairman, Pharmaceuticals Group, at Johnson & Johnson.  In this role, he is responsible for the Company’s global pharmaceutical commercial organizations.  He also has dotted line accountability for Operations, Quality and Compliance, groups which support the commercial, R&D and global marketing and access organizations.  He leads the Company’s Pharmaceuticals Group Operating Committee.

 Joaquin was named Company Group Chairman, North America Pharmaceuticals, in 2009, and later assumed expanded responsibility for Latin America.  He and his leadership team were responsible for the launch of four key products in a single year and for the continued growth of our Virology and Immunology franchises. Previously, he had been Company Group Chairman, Ortho Clinical Diagnostics, Inc., and a member of the Medical Devices & Diagnostics Group Operating Committee since 2007.

Before that, Joaquin’s career in the pharmaceutical segment spanned sales, marketing and general management.  He joined Johnson & Johnson in 1989 in Janssen Spain after working at Eli Lilly and Squibb.  He later became Managing Director of Janssen Cilag Italy and a leader at Ortho Biotech Europe before relocating to the United States in 2002 as Vice President for the Oncology Franchise at Ortho Biotech.  He was named President, Ortho Biotech Products, L.P. in 2005, and, during his tenure, the company sustained a leadership position in bioscience in difficult market conditions and under significant competitive pressure.

A native of Valencia, Spain, Joaquin holds an undergraduate degree in Economics and two Master’s degrees – one in Business Administration from ESADE in Barcelona; the other in International Management from Thunderbird in Phoenix, Arizona. 

×

Jennifer Finnegan McCafferty, Ph.D.
VP, Consumer Health Supply Chain, GlaxoSmithKline

Dr. Jennifer Finnegan McCafferty started her career in the pharmaceutical industry as a chemist with Merck & Co, Inc where she supported analytical development, technology transfer, new product introduction and troubleshooting for the global Merck manufacturing sites. Jennifer was with Merck for 11 years in site and central roles of increasing responsibility within the Analytical Development, Quality,  Stability, Commercialization, Process Analytical Technology and Regulatory organizations.  

In 2006, Jennifer moved to GSK (Research Triangle Park, NC) to develop and lead a new central quality team called the Laboratories Center of Excellence.    Her team developed global Quality Management Systems (QMS) standards for laboratory and stability controls, identified and implemented internal and external laboratory best practices in the worldwide Quality laboratories, and implemented Stability Shared Service laboratories.  In 2011, Jennifer was appointed VP & Head of the Product Quality Center of Excellence where, as a member of the Quality Executive Team, she developed a global organization focused on providing Quality scientific leadership and manufacturing site support to the new product pipeline, as well as targeted improvements to the GSK commercial product portfolio.  From 2012‐March 2014, Jennifer was VP of External Quality where she was responsible for the global quality operations management of all suppliers and contract manufacturing organizations utilized by the GMS Supply Chain.   Jennifer was recently appointed to the newly‐created role of VP, Consumer Healthcare Supply Chain Improvement Programme to drive delivery of ‘right first time’ operational performance across the Supply Chain.  Jennifer is particularly enthusiastic about driving organizational change, performance improvement and people development in GSK.

Jennifer has a bachelor’s degree from Colgate University Phi Beta Kappa with highest honors in Chemistry and a Ph.D. in Analytical Chemistry from the University of North Carolina at Chapel Hill.  Jennifer was previously active in the Pharmaceutical Research and Manufacturers of America (PhRMA) Analytical Technical Group and is currently a member of the Rx‐360 Board, GSK US Contributions Committee, University of North Carolina Chemistry Department Advisory Board and a number of other organizations promoting science and education in North Carolina.  Jennifer is married to Professor Dewey McCafferty (Duke University and a native of North Carolina).   They have a twelve-year old daughter and eight‐year old son who attend the public schools in Chapel Hill.

×

Margaret Hamburg
Commissioner, FDA

Dr. Margaret A. Hamburg is Commissioner of the Food and Drug Administration (FDA), where she has served since May 2009. As FDA Commissioner, she is advancing regulatory science, medical product innovation and globalization of the agency, while overseeing the implementation of groundbreaking laws to curb the use of tobacco and enhance food safety. She has undertaken major efforts to streamline and modernize FDA’s regulatory pathways. Before joining FDA, Dr. Hamburg was vice president and senior scientist at the Nuclear Threat Initiative. In the 1990s, as New York City's Health Commissioner, she launched several major initiatives, including the nation's first public health bioterrorism preparedness program and an internationally recognized program to curtail the resurgence and spread of TB. President Clinton later named her Assistant Secretary for Planning and Evaluation in the U.S. Department of Health and Human Services. Dr. Hamburg earned her M.D. from Harvard Medical School.

×

Colin Hill
CEO & President, GNS Healthcare

Colin Hill co‐founded GNS Healthcare in 2000 and has served as CEO since then. He brings years of hands‐on scientific experience to his role, with expertise in the areas of computational physics and systems biology. He also serves as Chairman of GNS Healthcare’s parent company Via Science, a leading big data analytics company focused on business intelligence, finance, and economic forecasting. He also serves on the Board of Directors of AesRx, a biopharmaceutical company dedicated to the development of a new treatment for sickle cell disease. Colin serves on the Advisory Board of the Boston Medical Center’s philanthropic trust and as the Chair of the Industrial Advisory Board of EBICS. Colin is the author of the “Healthcare 2020” blog on Forbes.com.

In 2004, Colin was named to MIT Technology Review’s TR100 list of the top innovators in the world under the age of 35. He is a frequent speaker at international scientific and industry conferences and has appeared in numerous publications and television segments, including The Wall Street Journal, CNBC Morning Call, Nature, Forbes, Wired, and The Economist. He graduated from Virginia Tech with a degree in physics and earned his master’s degree in physics from McGill University and Cornell University.

×

Mitch Horowitz
Vice President & Managing Director, Battelle Technology Partnership Practice

Mitch Horowitz has a strong record of accomplishment in technology development where he has worked as a principal economic development consultant, high ranking state development official and as an executive in a fast growing clinical trials informatics company.

Mr. Horowitz has been a national leader in developing bioscience cluster strategies dating back to his work as the consultant who developed Maryland’s widely acclaimed biotechnology strategy in the early 1990’s. Mr. Horowitz then joined the State of Maryland with the responsibility for implementing that strategy as Technology Advisor to the Secretary of Economic and Employment Development. While Technology Advisor in Maryland, Mr. Horowitz was directly involved in recommending state support for technology ventures and in establishing several technology development organizations, including the Maryland Health Care Product Alliance. Among his accomplishments with the State of Maryland was serving as the State’s program manager for a wide number of capital development projects including incubator projects in Montgomery County and the University of Maryland College Park, and the Maryland Biotechnology Processing Center.

As Vice President & Managing Director of Battelle’s Technology Partnership Practice, Mr. Horowitz has led many of Battelle’s biosciences roadmap assignments: including:

  • PhRMA Report on The Biopharmaceutical Research & Development Enterprise: Growth Platform for Economies Around the World, 2012
  • Biotechnology Industry Organization, Biennial Reports on the Biosciences Development Across the States (2012, 2010, 2008)
  • Utah Life Sciences Acceleration Strategy, 2012
  • Arizona Bioscience Roadmap and Arizona Translational Research Pathway Initiative including managing the ongoing implementation of the Arizona Translational Resource Network
  • Council on American Medical Innovation , Assessment of U.S. Medical Innovation System and National Agenda, 2010
  • Jordan National Biomedical Strategy, 2011
  • Maryland Life Sciences Initiative, 2009
  • Memphis Bioscience Positioning and Strategy (and Update Report), 2004 and 2009
  • Hillsborough County Biocomplex Assessment, 2009
  • The Sanford Project: A Unique Initiative to Advance Innovative Treatments for Diseases and Address Major Healthcare Issues, 2008
  • Georgia Bioscience Core Competencies and Identification of Major New Bioscience Initiative, 2006

Prior to joining Battelle’s Technology Partnership Practice, Mr. Horowitz spent six years working with a diversified technology firm. As part of his executive management responsibilities, Mr. Horowitz served as executive vice president for business development and marketing for a fast growing clinical trials informatics company, Capital Technology Information Services of Rockville, MD.  Mr. Horowitz served as Director for State and Local Development at the Corporation for Enterprise Development, a leading think tank on economic development policies.

Mr. Horowitz holds a Master’s in Public Policy from the Kennedy School of Government at Harvard University and a B.S. from Cornell University.

×

Robert J. Hugin
Chairman and CEO, Celgene Corporation

Mr. Hugin serves as Chairman and Chief Executive Officer of Celgene Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for unmet medical needs in cancer and immune-inflammatory disease.  He joined Celgene in June 1999 and has been a Director of Celgene since December 2001.  Mr. Hugin also serves as a Director of The Medicines Company, Atlantic Health System, Inc. and of Family Promise, a national non-profit network assisting homeless families. He serves as Chairman of The Pharmaceutical Research and Manufacturers of America and is a member of the Board of Trustees of The Darden Foundation, University of Virginia as well as a founding Board member of Choose NJ.  Prior to joining Celgene, Mr. Hugin was a Managing Director with J.P. Morgan & Co. Inc. Mr. Hugin received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985 and served as a United States Marine Corps infantry officer during the intervening period.  Bob and his wife Kathy have three children and live in Summit, New Jersey.

Read Robert Hugin's Incoming Chairman's Remarks at PhRMA's 2013 Annual Meeting in San Diego. 

Health Care Innovation & US Economy: CNBC Interviews Incoming PhRMA Chairman Hugin. Watch the interview here.

Protecting U.S. Medical Innovation: A Call To Action From Celgene's CEO

×

Suleika Jaouad
Author, "Life, Interrupted"

Suleika Jaouad (pronounced: su‐LAKE‐uh ja‐WAD) is a 25‐yr‐old Arab‐American journalist, blogger, women's health advocate and cancer survivor. She is the author of the Emmy Award‐ winning New York Times series “Life, Interrupted”.

Suleika’s career aspirations as a foreign correspondent were cut short when, at age 22, less than a year after graduating from Princeton with highest honors, she was diagnosed with leukemia. Over the course of the past three years, Suleika has under gone dozens of rounds of chemotherapy, a life‐saving clinical trial and a bone marrow transplant. But cancer didn't stop her from pursuing her dreams to become a writer.

Suleika started writing and videotaping her experiences navigating the health care system as a young woman living with cancer within weeks of her diagnosis. At age 23, in the Spring of 2012, she became one of the youngest New York Times journalists, and began to writing her column “Life, Interrupted”, from the bone marrow transplant unit at Memorial Sloan‐Kettering Cancer Center.

Through her column, an accompanying video series, photography and social media, Suleika has become a pioneer in new approaches to science and health journalism. She has also written for Glamour Magazine, Women's Health, and the Huffington Post. She is has contributed to NPR's Talk of The Nation and All Things Considered and has appeared on NBC's Today Show, ABC News, Everyday Health and NY1.

Her unique fashion sense has also garnered the attention of fashion designers such as Prabal Gurung, who named Suleika the first muse in his Monday Muse series.

Suleika is an Angel Ambassador to Gabrielle’s Angel Foundation and has gained support and praise for her work by celebrities, influencers, and trend setters such as Katie Couric, Denise Rich, Smokey Robinson, Lance Armstrong, Kim Kardashian, and Arianna Huffington.

Suleika believes we all have life interrupted moments whether dealing with a health crisis, unemployment, or a bad breakup.Suleika’s happened to be cancer. But it’s not the interruption that matters. It’s how we cope with it. But how we learn from it and grow beyond it.

×

Richard Kingham
Partner, Covington & Burlington LLP

Richard Kingham is a partner in the law firm of Covington & Burling LLP, assigned to the Washington and London offices. Since joining the firm in 1973, he has concentrated on regulation of pharmaceuticals and other medical products. He has advised most of the major pharmaceutical manufacturers in the United States and Europe as well as trade associations of the pharmaceutical and biotechnology industries. He has served on committees of the Institute of Medicine of the National Academy of Sciences, the National Institutes of Health, and the World Health Organization. He acted as counsel to the Global HIV Vaccine Enterprise and the Institute for One World Health, and he was a member of a working group of the Center for Global Development on systems to expedite clinical research on vaccines and drugs for diseases in developing countries. He recently served on a working group established by the Pharmaceutical Law Institute of Tsinghua University School of Law in Beijing to make recommendations for reform of the pharmaceutical regulatory system in China. He has  lectured on pharmaceutical law at the University of Virginia School of Law, Cardiff University, and King’s College London and serves an adjunct professor at the Georgetown University Law Center.

×

John C. Lechleiter, Ph.D.
Chairman, President, & CEO, Eli Lilly & Company

John C. Lechleiter, Ph.D., has served as president and chief executive officer of Eli Lilly and Company since April 1, 2008.  He became chairman of the board of directors on January 1, 2009.

Lechleiter joined Lilly in 1979 as a senior organic chemist in process research and development and became head of that department in 1982.  In 1984, he began serving as director of pharmaceutical product development for the Lilly Research Centre Limited in Windlesham, England.

He returned to the United States in 1986 as manager of research and development projects for Europe. In 1988, he became director of development projects management, and he assumed additional responsibility for pharmaceutical regulatory affairs the following year. In 1991, Lechleiter was named executive director of pharmaceutical product development, and he became vice president in 1993.  He was appointed vice president of regulatory affairs in 1994, was named vice president for development and regulatory affairs in 1996, and became senior vice president of pharmaceutical products in 1998.

In 2001, Lechleiter was appointed executive vice president for pharmaceutical products and corporate development.  In 2004, he became Lilly’s executive vice president for pharmaceutical operations.  And in 2005, he was named president and chief operating officer and joined the board of directors.

Lechleiter received a bachelor of science degree in chemistry from Xavier University (Cincinnati, Ohio) in 1975.  He subsequently studied organic chemistry as a National Science Foundation Fellow at Harvard University, where he received his master’s and doctorate degrees in 1980.  Lechleiter has received honorary doctorates from Marian University (Indianapolis, Indiana), the University of Indianapolis, the National University of Ireland, and Indiana University.

Lechleiter is a member of the American Chemical Society and Business Roundtable. He serves on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA), as president of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), as chairman of the U.S.-Japan Business Council, and on the boards of United Way Worldwide, Xavier University (Cincinnati, Ohio), the Life Sciences Foundation, and the Central Indiana Corporate Partnership. He also serves on the boards of Nike, Inc. and Ford Motor Company.

×

Jonathan S. Leff
Partner, Deerfield Management

Jonathan S. Leff is a partner with healthcare investment firm Deerfield Management and Chairman of the Deerfield Institute.  Mr. Leff focuses on venture capital and private equity investments in life sciences.  Prior to joining Deerfield, for more than 16 years Mr. Leff was with Warburg Pincus, where he led the firm’s investment efforts in biotechnology and pharmaceuticals.  Mr. Leff has also been active in public policy discussions related to healthcare and medical innovation.  He serves as a member of the Executive Committee of the Board of the National Venture Capital Association (NVCA) and leads NVCA’s life sciences industry efforts as Chair of NVCA’s Medical Innovation and Competitiveness Coalition (NVCA‐MedIC), and he also serves on the Emerging Companies Section Board of the Biotechnology Industry Organization.  Mr. Leff is a member of several not‐for‐profit Boards, including the Spinal Muscular Atrophy Foundation, Friends of Cancer Research, and the Columbia University Medical Center Board of Advisors.

×

J. Leonard Lichtenfeld
MACP Deputy Chief Medical Officer , American Cancer Society, Inc.

Dr. Lichtenfeld is Deputy Chief Medical Officer for the American Cancer Society. Among his responsibilities is directing the Society’s Cancer Control Science Department.  This group of internationally recognized experts focuses on the prevention and early detection of cancer, as well as emerging science and trends in cancer.  The department is responsible for producing the Society’s widely recognized guidelines for the prevention and early detection of cancer, including the role of nutrition and physical activity. Dr. Lichtenfeld oversees the Society’s cancer control programs in health disparities and serves as the medical advisor to the Society’s nationwide Laureate program.  He is well known for his blog (www.cancer.org/drlen) which addresses topics related to cancer care.

Dr. Lichtenfeld is recognized as a resource both within and outside the Society for his expertise in oncology and medical affairs.  He serves as a liaison for the Society with many professional and public organizations, and is a frequent spokesperson on behalf of the Society on a variety of cancer related subjects. 

A board certified medical oncologist and internist who was a practicing physician for over 19 years, Dr. Lichtenfeld has long been active in medical affairs on a local, state, and national level.  He is active in several state and national medical organization and advisory committees and has a long‐standing interest in legislative and regulatory issues, medical care delivery, the role of health information technology in healthcare and physician payment. 

Dr. Lichtenfeld is a graduate of the University of Pennsylvania and Hahnemann Medical College

(now Drexel University College of Medicine) in Philadelphia.  His postgraduate training was at Temple University Hospital in Philadelphia, Johns Hopkins University School of Medicine and the National Cancer Institute in Baltimore. He is a member of Alpha Omega Alpha, the national honor medical society.  Dr. Lichtenfeld has received several awards in recognition of his efforts on behalf of his colleagues and his professional activities.  He has been designated a Master of the American College of Physicians in acknowledgement of his contributions to internal medicine.  

Dr. Lichtenfeld is married, and resides in Atlanta and Thomasville, Georgia. 

×

Terry McAuliffe
Governor, Virginia

Terence "Terry" McAuliffe is the 72nd Governor of Virginia. He is a successful businessman, entrepreneur, and dad who has lived in Virginia for more than 20 years. He previously served as Chairman of the Democratic National Committee from 2001 to 2005, was co-chairman of President Bill Clinton's 1996 re-election campaign, and was chairman of Hillary Clinton's 2008 presidential campaign. 

In politics and business, McAuliffe has worked with people from all walks of life and different political backgrounds. Since becoming governor, he has focused on working in a bipartisan way to help grow Virginia’s economy, expand access to health care, and increase educational opportunities for students.  

Governor McAuliffe is also dedicated to ensuring that Virginia is open and welcoming to all.  That is why on his first day in office, he signed Executive Order Number 1, which prohibits discrimination in state government based on sexual orientation or gender identity. 

Terry and his wife Dorothy were married in 1988. They’ve attended St. Luke Catholic Church for two decades and have been involved in every sport, activity, and competition imaginable with their five children Dori, Jack, Mary, Sally, and Peter. 

×

Craig C. Mello, Ph.D.
Investigator, Howard Hughes Medical Institute

Dr. Craig C. Mello is an Investigator of the Howard Hughes Medical Institute, the Blais University Chair in Molecular Medicine and Co‐director of the RNA Therapeutics Institute at the University of Massachusetts Medical School.

Dr. Mello’s lab uses the nematode C. elegans as a model system to study embryogenesis and gene silencing. His collaborative work with Dr. Andrew Fire led to the discovery of RNA interference (RNAi), for which they shared the 2006 Nobel Prize in Physiology or Medicine. Together they showed that when C. elegans is exposed to double‐stranded ribonucleic acid – dsRNA, a molecule that mimics a signature of viral infection, the worm mounts a sequence‐specific silencing reaction that interferes with the expression of cognate cellular RNAs. For the layperson, RNAi is the cell’s search engine; the Google of the cell. Using readily produced short synthetic dsRNAs, researchers can now submit their own RNAi search queries to silence any gene in organisms as diverse as corn and humans. RNAi allows researchers to rapidly “knock out” the expression of specific genes and to thus define the biological functions of those genes. RNAi also provides a potential therapeutic avenue to silence genes that contribute to disease.

Before the Nobel Prize, Dr. Mello’s work on RNAi was recognized with several awards including the National Academy of Sciences Molecular Biology Award, the Canadian Gairdner International Award, the Paul Ehrlich‐and Ludwig Darmstaedter Award, and the Dr. Paul Janssen Award for Biomedical Research. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society.

×

Jessica Melore
Motivational Speaker, Heart Attack Survivor

Jessica Melore is an international motivational speaker who has spoken for crowds spanning 10 to 10,000 people. A survivor of a massive heart attack, heart transplant, leg amputation, and cancer, by age 20 she had overcome more challenges than many face in a lifetime. A 31‐year‐old graduate of Princeton University, she was named one of GLAMOUR Magazine’s Top 10 College Women of 2002. Television appearances include Good Morning America, Dateline NBC, ABC Nightly News, NBC Nightly News with Chuck Scarborough, Extra!, Hard Copy, MTV, Channel 13 and Telemundo. She has also appeared on 95.5 WPLJ and in several publications, including Woman’s Day, New York Daily News, Wall Street Journal, AOL Health, In Motion, National Geographic Explorer for Kids, USTA Magazine and written for GLAMOUR, Cosmopolitan, MariaShriver.com, and the Huffington Post. Formerly the youngest board member for the Leukemia & Lymphoma Society, she currently serves as a national survivor ambassador. She is an original founding member and board member of Harboring Hearts, a non‐profit dedicated to providing heart patients and their family with emotional and financial assistance during a time of need. She has served on the National Advisory Council for Donate Life America, and as a patient spokesperson for the American Heart Association and American Cancer Society. She is also member of the National Kidney Foundation’s transAction executive committee. Honors include Princeton University’s Allen Macey Dulles Award for the graduating senior who best represents Princeton’s motto, “Princeton in the Nation’s Service and in the Service of All Nations”. Melore was also named the YWCA’s “Woman of Inspiration” of 2002, which “recognizes a woman who has overcome adversity in her life to make a profound impact on others,” and received the “Spirit of Somerset” Award in 2001 for outstanding youth leadership. The “Jessica Melore Award” was developed by the Somerville Education Association as a community service award. Her amazing story of courage and determination has been what Extra! called an “inspirational tale of survival that gives us all hope”. Visit www.JessicaMelore.com for more information.

×

Ambassador Hugo Paemen
Consultant, Brussels,

Hugo Paemen is Senior Advisor on EU, International trade and regulatory affairs.

Prior to joining HoganLovells, Ambassador Paemen served, from 1995 to 1999, as head of the European Commission’s Washington Delegation. From 1987 until 1995 he was Deputy Director – General for External Relations at the European Commission, and, in that capacity, he was the EU’s chief negotiator during the Uruguay Round, which resulted in a number of international trade agreements and eventually led to the creation of the World Trade Organization (WTO).

From 1985 to 1987 he was the official spokesman of the European Commission, headed by Jacques Delors, and, from 1978 to 1985, ‘chef de cabinet’ of Vice‐President Viscount Davignon.

A career diplomat, Hugo Paemen was, from 1969 to 1974, the spokesman of the Belgian Foreign Ministry and held positions at the Belgian Embassies in Paris (1965‐1969) and Washington (Economic Minister from 1974‐1977).

In 2000, the King of Belgium awarded Ambassador Paemen the title of Baron in recognition of his contributions, as a diplomat, to the Belgian State and o the European Union.

He is currently co‐Chairman of the TransAtlantic Business Council (TABC).

Hugo Paemen lectured on European Policy and Integration Problems at Georgetown University (Washington, DC), the College of Europe in Natolin (Poland) and the Catholic University of Leuven

(Belgium).

He authored “From the Gatt to the WTO: the European Community in the Uruguay Round”, and has contributed to several publications writing articles relating to current diplomatic and trade issues.

He co‐authored: “A New Era for Transatlantic Leadership, A Report from the Transatlantic Task Force on Trade and Investment (2012). Ambassador Paemen holds his M.A. from Katholieke Universiteit Leuven.

Ambassador Paemen holds his M.A. from Katholieke Universiteit Leuven. 

×

Eric Perakslis, PhD
Executive Director, Center for Biomedical Informatics & Countway Library of Medicine, Harvard Medical School

Eric is the Executive Director of the Center for Biomedical Informatics and the Countway Library of Medicine at Harvard Medical School.  Eric was most recently the Chief Information Officer and Chief Scientist (Informatics) at the U.S. Food and Drug Administration.  In this role, Eric authored the first IT Strategic Plan for FDA and was responsible for modernizing and enhancing the IT capabilities as well as the in silico scientific capabilities at FDA. 

Eric serves on the editorial board of Cancer Today magazine and serves on the editorial board and as the Associate Editor for Novel Communications for the DIA flagship publication, the Journal of and Therapeutic Innovation and Regulatory Science.  Eric also serves as the Vice Chair of the Advisory Committee for the American Society of Clinical Oncology CancerLinQ project and on several scientific advisory boards including the SAB of NuMedii and the leadership team of Precision for Medicine.

Prior to FDA, Eric was Senior Vice President of R&D Information Technology at Johnson & Johnson Pharmaceuticals R&D and was a member of the Corporate Office of Science and Technology.  During his thirteen years at J&J, Eric also held the posts of Vice President R&D Informatics, Vice President and Chief Information Officer, Director of Research Information Technology as well as assistant Director and Director of Drug Discovery Research prior to his current role.  Before joining J&J, Eric was the Group leader of Scientific Computing at ArQule Inc. and he began his professional career with the Army Corps of Engineers.

Eric has a PhD in chemical and biochemical engineering from Drexel University and also holds B.S.Che and M.S. degrees in chemical engineering.  Eric’s current research interests are enterprise knowledge management, patient stratification, healthcare IT and translational informatics with the specific focus on precompetitive data sharing, risk‐‐‐based analytics and open source systems globalization.

Eric is a late‐stage kidney cancer survivor and an avid patient advocate.  He has served as the Chairman of the Survivor Advisory Board at the Cancer Institute of New Jersey and as the Chief Information Officer of the King Hussein Institute for Biotechnology and Cancer in Amman, Jordan. 

Eric has also worked extensively with the Lance Armstrong Foundation, the Kidney Cancer Association, the ScientistóSurvivor program of the American Association for Cancer Research, OneMind4Research, Faster Cures and several other top non‐profit disease‐based organizations to further their domestic and international agendas.  

Eric’s personal interests include sailboat racing, backcountry snowboarding, rock climbing, cycling, triathlons, marathons and operating his family vineyard and winery.  Eric lives in Doylestown, Bucks County Pennsylvania with his wife Lisa Gail and 12‐year old daughter Sammy.

×

Tomas J. Philipson
Daniel Levin Professor of Public Policy Studies , Irving B. Harris Graduate School of Public Policy Studies University of Chicago

Tomas J. Philipson is the Daniel Levin Professor of Public Policy Studies in the Irving B. Harris Graduate School of Public Policy Studies at the University of Chicago, and a Founding Partner of Precision Health Economics. Philipson has also served in several public sector positions. He served as the senior economic advisor to the head of the Food and Drug Administration (FDA) during 2003‐04 and to the head of the Centers for Medicare and Medicaid Services (CMS) in 2004‐05. Philipson is the recipient of numerous international and national research awards. He has twice (in 2000 and 2006) been the recipient of the highest honor of his field: the Kenneth Arrow Award of the International Health Economics Association (for best paper in the field of health economics). In addition, he was awarded the Garfield Award by Research America in 2007 (for best paper in the field of health economics). Dr. Philipson received his MA and PhD in economics from the Wharton School at the University of Pennsylvania.

×

Richard F. Pops
CEO and Director, Alkermes, Inc.

Richard Pops has been Chief Executive Officer of Alkermes since February 1991. A native of Los Angeles, California, Richard received a B.A., in Economics from Stanford University in 1983.  From 1984 to 1991, he was employed by PaineWebber, Inc., in New York as Vice President of PaineWebber Development Corporation, providing product development financing for the country's leading biotechnology and high-technology companies.

Under Richard's leadership, Alkermes has grown from a privately held company with 25 employees to a publicly traded, leading specialty pharmaceutical company (NASDAQ:ALKS) with more than 400 employees in multiple locations in the United States. The company has raised over $600 million to support the research and development of its product candidates and has consummated important strategic alliances with major pharmaceutical companies, including: Serono, S.A., Eli Lilly and Company, Genentech, Inc., and Janssen Pharmaceutica, Inc.

Mr. Pops currently serves on the Board of Directors of: Alkermes, Inc.; Neurocrine Biosciences, Inc.; Reliant Pharmaceuticals, LLC; CombinatoRx, Inc.; Expressive Constructs, Inc.; the Biotechnology Industry Organization (BIO)(former Chairman); the Massachusetts Biotechnology Council (MBC); the New England Healthcare Institute (NEHI); Harvard Medical School Board of Fellows and The Fessenden School Board of Trustees. He also serves as Chair for the Harvard Medical School Advisory Council for Biological Chemistry & Molecular Pharmacology (BCMP) and is an Advisory Board Member of Polaris Venture Partners.

×

Daniel M. Price
Managing Director , Rock Creek Global Advisors LLC

Daniel M. Price is Managing Director of Rock Creek Global Advisors, an international economic policy advisory firm, where he focuses on international regulatory and policy matters. Mr. Price is currently advising multinational companies, financial institutions, and trade associations on financial regulatory issues, policy matters arising in global forums (G8, G20, and APEC), and ongoing trade negotiations. 

Mr. Price co‐founded Rock Creek Global Advisors in July 2011. Previously, Mr. Price served in the Administration of George W. Bush as the senior White House official responsible for international trade and investment, development assistance, and the international aspects of financial reform, energy security, and climate change.

Mr. Price was the President’s personal representative to the G8, the G20 Financial Summit, and the Asia‐Pacific Economic Cooperation Forum. He was US chair of cabinet‐level economic dialogues with Brazil, India, and the European Union. 

Before and after his White House service, Mr. Price was a partner with Sidley Austin LLP, having founded and chaired the firm’s 60‐member International Trade & Dispute Resolution group. Mr. Price counseled multinational companies on trade, investment, national security, and sanctions issues, and represented companies and governments in WTO, investment treaty, and

NAFTA disputes. Earlier, Mr. Price served as USTR Principal Deputy General Counsel and as Deputy Agent to the Iran‐US Claims Tribunal in The Hague. 

He currently serves on the Panel of Arbitrators of the World Bank’s International Centre for Settlement of Investment Disputes, the Advisory Board of the Atlantic Council, and the Board of Directors of the American Arbitration Association. 

Mr. Price has appeared on BBC, CNBC, PBS, and Bloomberg TV. His articles have been published in the New York Times, Financial Times, Washington Post, International Herald Tribune, Politico, and the Wall Street Journal. 

Mr. Price was educated at Haverford College, Cambridge University, and Harvard Law School, where he was Articles Editor of the Harvard Law Review. 

×

Ian Read
CEO, Pfizer

Ian Read is Chief Executive Officer of Pfizer, the world's largest research-based biopharmaceutical company, which discovers, develops, manufactures and markets a broad portfolio that spans the entire spectrum of human and animal health products. He is also a member of the company's Board of Directors.

Previously, he served as Senior Vice President, Pfizer Inc, and Group President of the Worldwide Biopharmaceutical Businesses, which he led from 2006 through December 2010. In that role, he oversaw five global business units — Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.

Ian began his career with Pfizer in 1978 as an operational auditor. He worked in Latin America through 1995, holding positions in a number of Pfizer's largest, fastest-growing operations, including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, Ian was appointed President of Pfizer's International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in 2002. Ian later became accountable for operations in both the Africa/Middle East region and Latin America as well.

Ian received his B.Sc. in chemical engineering from London University Imperial College in 1974. He earned his Chartered Accountants certification from the Institute of Chartered Accountants of England and Wales in 1978.

Ian serves on the Board of Kimberly-Clark as well as on the U.S. Council for International Business and the European Federation of Pharmaceutical Industries and Associations.

×

Geralyn S. Ritter
Senior Vice President, Global Public Policy & Corporate Responsibility, Secretary and Assistant General Counsel , Merck & Co., Inc.

Geralyn S. Ritter is Senior Vice President, Global Public Policy & Corporate Responsibility, Secretary and Assistant General Counsel at Merck & Co., Inc. in Whitehouse Station, New Jersey.  She is responsible for worldwide public policy, government affairs and corporate responsibility matters, as well as leading Merck's philanthropic initiatives.  As Corporate Secretary, Ms. Ritter is also responsible for coordinating and supporting the activities of the Company's Board of Directors, leading shareholder engagement on governance matters, ensuring compliance with statutory and regulatory requirements applicable to a public company, and counseling directors and executive officers regarding their responsibilities under Section 16 of the Securities Exchange Act of 1934.  Ms. Ritter also oversees legal support for the Company's corporate areas, with responsibility for securities, finance, public affairs, benefits and executive compensation matters.  Ms. Ritter serves as President of the Merck Foundation.  

Prior to joining Merck in 2008, Ms. Ritter was Senior Vice President for International Affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA) in Washington, DC.  Prior to joining PhRMA, Ms. Ritter served as Trade Counsel at the Washington law firm of Covington & Burling.  Ms. Ritter also served for three years as Associate General Counsel for intellectual property matters at the Office of the U.S. Trade Representative.  

Ms. Ritter received a Masters degree in International Studies from the School of Advanced International Studies (SAIS) at Johns Hopkins University.  She received her law degree from the Stanford University School of Law in Palo Alto, California, and her undergraduate degree in economics and political science from Duke University in Durham, North Carolina. 

Ms. Ritter is married and has three sons. 

×

Carl Schmid
Deputy Executive Director, The AIDS Institute

Carl Schmid was named Deputy Executive Director of The AIDS Institute, a national public policy, advocacy and research organization, in June, 2009. Prior to that he served as the Institute’s Director of Federal Affairs, a position he held since February 2004. Prior to joining The AIDS Institute, he served as a consultant to a number of HIV/AIDS and civil rights organizations. He has worked in Washington for over 20 years, and began his public policy work in the energy arena, which continued through 2003. 

Mr. Schmid is co‐chair of the AIDS Budget and Appropriations Coalition; a Convening Group member of the Federal AIDS Policy Partnership, and co‐chair of an HIV Testing Reimbursement Work Group. He is a former chair of the HIV Prevention Action Coalition and the Ryan White Reauthorization Work Group. He remains active in those coalitions along with others that advocate for Medicaid, Medicare, and Healthcare Reform; the AIDS Drug Assistance Program (ADAP), and Hepatitis issues. 

He was a member of the Presidential Advisory Council on HIV/AIDS from 2007 to 2009, and Chaired its Domestic Subcommittee. In 2010 he was named by POZ Magazine as one of the 100 most effective AIDS fighters in the nation and was recently named by Whitman Walker Health as one of the 25 individuals who have played prominent roles in the fight against HIV/AIDS in DC over the past 25 years. 

Mr. Schmid earned a B.A. in Public Affairs and a M.B.A. in International Affairs from the George Washington University in Washington, D.C.

 

×

Wendy K.D. Selig
President and CEO, Melanoma Research Alliance

Wendy K.D. Selig is President and CEO of the Melanoma Research Alliance (MRA), a public charity focused on finding and funding the most promising melanoma research worldwide to accelerate progress toward a cure.   Ms. Selig drives and manages MRA’s strategic priorities, research portfolio, and day‐to‐day operations. Under her leadership, MRA is accelerating progress toward a cure for melanoma by supporting an international, cross‐disciplinary group of biomedical researchers exploring, identifying, and pursuing innovative, transformative research.  

Prior to joining the MRA, Ms. Selig spent nearly a decade in leadership positions at the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN). She currently chairs the Board of Directors of the National Coalition of Cancer Research (NCCR), and is a member of the Government Affairs Committee of the

Prostate Cancer Foundation (PCF), and the Patient Leadership Council (PLC) of the Clinical Trials Transformation Initiative (CTTI).  She previously served as Chair of the United for Medical research (UMR) coalition and a member of the Directors Consumer Liaison Group (DCLG) at the National Cancer Institute (NCI).  From 1989‐2000, Ms. Selig served on Capitol Hill as a top aide for U.S. Representative Porter J. Goss (R‐FL), the House Rules Committee and the House Permanent Select Committee on Intelligence (HPSCI).  Ms. Selig is a Magna Cum Laude graduate of Princeton University and holds a Masters in Science from Northwestern University’s Medill School of Journalism.

×

Daniel Tassé
Chairman and CEO, Ikaria

Daniel Tassé has served as Ikaria Inc.’s President, Chief Executive Officer, and member of the Board of Directors since 2008.  In October 2009, he was appointed Chairman of the Board of Directors.

In 2013, Mr. Tassé oversaw the spin out of Bellerophon Therapeutics from Ikaria, creating two companies to best leverage the scientific, financial and marketing strengths of the company.  

Prior to joining Ikaria, Mr. Tassé served as General Manager of the Pharmaceuticals and Technologies Business Unit of Baxter International, a division which was created by integrating the company’s Anesthesia & Critical Care, Hospital I.V. Drug and BioPharma Solutions Business Units.  Earlier in this career, Mr. Tassé held a number of senior management positions at GlaxoSmithKline; from 2001 to 2004 he was Vice President and Regional Director for Australasia at GSK.

Mr. Tassé is a member of the Healthcare Leadership Council, a member of the Board of Directors of the Roundtable on Critical Care Policy, and Chairman of the Foundation on National Critical Care Policy.  He also is a member of the Board of Directors and Health Section Governing Board of the Biotechnology Industry Organization (BIO), where he participates on the bioethics, regulatory environment and reimbursement committees. Additionally, Mr. Tassé is a member of the Board of Directors of the Pharmaceutical Research and Manufacturers Association of America (PhRMA), where he participates on the FDA and Biomedical Research Committee.  He earned a B.Sc. in Biochemistry from the University of Montreal.

With Mr. Tassé’s extensive track record in the healthcare industry comes a wealth of knowledge and dedication for the drug device combination space, the hospital market and for critical care in particular.  Under his leadership, Ikaria is developing innovative therapies that directly impact patient outcomes and has become a leader in the critical care space.

×

Sharon F. Terry
President and CEO , Genetic Alliance

Sharon F. Terry is President and CEO of Genetic Alliance, a network of more than 10,000 organizations, of which 1,200 are disease advocacy organizations. Genetic Alliance enables individuals, families, and communities to reclaim their health and become full participants in translational research and services.

She is the founding CEO of PXE International, a research advocacy organization for the genetic condition pseudoxanthoma elasticum (PXE). As co-discoverer of the gene associated with PXE, she holds the patent for ABCC6 to act as its steward and has assigned her rights to the foundation. She developed a diagnostic test and conducts clinical trials. She is the author of 120 peer-reviewed papers, of which 30 are PXE clinical studies.

Sharon is also a co-founder of the Genetic Alliance Registry and Biobank. In her focus at the forefront of consumer participation in genetics research, services, and policy, she serves in a leadership role on many of the major international and national organizations, including the Institute of Medicine (IOM) Science and Policy Board, the IOM Roundtable on Translating Genomic-Based Research for Health, the PubMed Central National Advisory Committee, the International Rare Disease Research Consortium Executive Committee, PhenX, Global Alliance, and as Founding President of EspeRare Foundation. She is on the editorial boards of several journals. She was instrumental in the passage of the Genetic Information Nondiscrimination Act. She received an honorary doctorate from Iona College for her work in community engagement in 2005; the first Patient Service Award from the UNC Institute for Pharmacogenomics and Individualized Therapy in 2007; the Research!America Distinguished Organization Advocacy Award in 2009; and the Clinical Research Forum and Foundation’s Annual Award for Leadership in Public Advocacy in 2011. In 2012, she became an honorary professor of Hebei United University in Tangshan, China, and received the Facing Our Risk of Cancer Empowered (FORCE) Spirit of Empowerment Advocacy Award. She was named one of FDA’s “30 Heroes for the Thirtieth Anniversary of the Orphan Drug Act” in 2013. She is an Ashoka Fellow.

She has received three first place prizes in competitions for the Platform for Engaging Everyone Responsibly (PEER) totaling more than $350,000. PEER was named one of "Six Business Models that are Transforming Health Systems around the World" in 2013.

×

Kenneth Thorpe, PhD
Robert W. Woodruff Professor and Chair, Rollins School of Public Health

Kenneth Thorpe, Ph.D., is the Robert W. Woodruff Professor and Chair of the Department of Health Policy & Management, in the Rollins School of Public Health of Emory University,

Atlanta, Georgia. Dr Thorpe is a member of the International Advisory Board for APCO

Worldwide. In addition, he serves as the Chairman of the Partnership to Fight Chronic Disease (PFCD). As Chairman of PFCD), Thorpe works with an international coalition organizations consisting of patients, providers, community organizations, business and labor groups, and health policy experts to raise awareness of the negative impact chronic disease has on health and economy.  He is also co‐chair of the Partnership for the Future of Medicare, a bipartisan group designed to ensure the sustainability of the program. Dr. Thorpe is also a member of the International Advisory Council for APCO Worldwide, a global communication firm.

In addition to holding a number of faculty positions, Thorpe was Deputy Assistant Secretary for Health Policy in the U.S. Department of Health and Human Services from 1993 to 1995. In this capacity, he coordinated all financial estimates and program impacts of President Clinton’s health care reform proposals for the White House. He also directed the administration’s estimation efforts in dealing with Congressional health care reform proposals during the 103rd and 104th sessions of Congress.

As the Chairman of the PFCD and respected health care expert, Thorpe regularly testifies before numerous committees in the U.S. Congress and in front of governments around the world on the aspects of health care reform, including disease prevention, wellness and coordination of care. 

Thorpe received his Ph.D. from the Pardee Rand Graduate School, an M.A. from Duke University and his B.A. from the University of Michigan.

×

Fred Upton
Chairman , House Energy and Commerce Committee

Congressman Fred Upton, R-St. Joseph, is proud to represent the commonsense values of Southwest Michigan. Since 2011, Fred has served as Chairman of the House Energy and Commerce Committee, which has jurisdiction over matters concerning health care, energy, the environment, telecommunications, commerce, manufacturing, and trade, as well as oversight and investigations.

Prior to his election to Congress, Fred worked for President Ronald Reagan in the Office of Management and Budget (OMB). While at OMB, he learned from President Reagan’s example that it does not matter who gets the credit, as long as the job gets done.

Fred has a well-earned reputation for getting things done in Washington and at home in Southwest Michigan.

Fred is focused on common-sense policies that promote job creation and economic growth; ensure government keeps pace with the innovation era and is transparent and accountable to taxpayers; and keep families and communities safe.

Under his chairmanship, Fred’s Committee has built a record of bipartisan success on public health issues, with ten bills already signed into law in the 113th Congress. Among those achievements is legislation to: advance research for children with rare and genetic diseases; strengthen the prescription drug supply chain in order to protect families against counterfeit drugs; permit research on organ transplants involving HIV-positive individuals; and streamline the federal approval process for new and generic drugs.

Under Fred's leadership, over the coming years his committee will take a comprehensive look at the full arc of accelerating cures to help provide patients with better access to treatments and trails, and to ensure the United States maintains its leadership role in health research and care. This is the first time Congress has begun such an effort.

Fred was born on April 23, 1953 and holds a bachelor’s degree in journalism from the University of Michigan. He and his wife Amey have two children.

×

Mark Velleca, M.D., Ph.D.
Executive Vice President, Chief Policy & Advocacy Officer , The Leukemia & Lymphoma Society (LLS)

Dr. Velleca heads LLS's office of public policy in Washington D.C. In this position, he oversees the strategy and implementation of LLS's legislative and regulatory policy initiatives. Dr. Velleca is also responsible for patient advocacy and patient and healthcare professional education at LLS. 

A scientist and board‐certified physician, Dr. Velleca has experience in both academic research and clinical medicine as well as executive management in the private sector. He was the founder and senior vice president of CGI Pharmaceuticals, guiding CGI from its inception through its establishment as a drug discovery company that brought multiple drug candidates from research into clinical trials. Gilead Sciences acquired CGI in 2010 and Dr. Velleca served as a senior advisor at Gilead until joining LLS in 2012. He has served on the board of directors and scientific advisory boards of several other biotechnology companies.

Earlier in his career, Dr. Velleca was an attending physician at Yale‐New Haven Hospital and on the clinical faculty at Yale Medical School. He earned a B.S. Cum Laude from Yale University and an M.D. and a Ph.D. from Washington University in St. Louis.

×

Christopher A. Viehbacher
CEO, Sanofi

Christopher A. Viehbacher, holds German and Canadian nationalities. He is a graduate of the Queens University (Ontario - Canada) and a certified public accountant. Since December 2008, he has held the position of Chief Executive Officer, Sanofi and is a Board member, in addition to being a member of the Strategy Committee. He is also Chairman of Genzyme, which Sanofi acquired in February 2011.

Christopher started his career in finance at PriceWaterhouseCoopers and joined GlaxoSmithKline (GSK) in 1988. Throughout the next 20 years with the company, he acquired broad international experience in Europe, in the United States and in Canada. His last position, before joining Sanofi was President, Pharmaceutical Operations North America. He was also a member of the board and Co-Chairman of the Portfolio Management Board.

Christopher was elected President of the EFPIA (European Federation of Pharmaceutical Industries and Associations) in June 2013 for a period of 2 years.

Christopher was Chairman of PhRMA in the United States (December 2010 – April 2012) and since February 2011 is Chair of the CEO Roundtable on Cancer. This association brings together employers across the United States to develop and implement workplace initiatives that reduce the risk of cancer, enable early diagnosis, facilitate better access to best-available treatments and hasten the discovery of novel and more effective diagnostic tools and anti-cancer therapies. Over 120 organisations are now members, covering 3 million employees.

In 2003, the French government acknowledged his commitment to public health and business by awarding Christopher a knight of the French Legion of Honor. He received the prestigious 2012 Pasteur Foundation Award, recognizing his leadership role within the pharmaceutical industry’s support of research & development and improving health of the 7 billion people around the world. Amongst other commitments, Christopher is also a member of International Business Council (WEF) and a member of the Board of Visitors of Fuqua School of Business, Duke University.

×